Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 8/19/2025

Multiple Endocrine Neoplasia Type 1 (MEN1) Syndrome

Diagnosis and Screening

  • The American College of Medical Genetics recommends genetic testing for MEN1 gene mutations, comprehensive biochemical screening for the three main constituent tumors (parathyroid, pancreatic, and pituitary), and appropriate imaging studies to detect tumors at an early stage in patients suspected of having MEN1 syndrome 1
  • A diagnosis of MEN1 can be made in individuals with two or more major MEN1-associated tumors (parathyroid, pancreatic neuroendocrine, pituitary), as suggested by the Endocrine Society 1, 2
  • The National Comprehensive Cancer Network recommends that any individual under age 30 with primary hyperparathyroidism (PHPT), pancreatic precursor lesions, or pancreatic islet tumor should be evaluated for MEN1 syndrome 1
  • Gastrinoma at any age, multiple pancreatic neuroendocrine tumors, parathyroid adenoma diagnosed before age 30, or multiglandular or recurrent parathyroid adenomas are indications for MEN1 syndrome evaluation 1, 2

Clinical Evaluation

  • A detailed family history focusing on endocrine disorders and tumors is essential in the evaluation of MEN1 syndrome, and physical examination to identify features of MEN1 (angiofibromas, collagenomas, lipomas) is recommended 3

Biochemical Screening

  • Serum calcium (corrected for albumin) and parathyroid hormone (PTH) levels should be measured in patients with suspected parathyroid disease, and fasting serum gastrin, fasting glucose, insulin, proinsulin, pancreatic polypeptide, glucagon, and chromogranin A levels should be measured in patients with suspected pancreatic neuroendocrine tumors 3

Imaging Studies

  • Abdominal CT or MRI with contrast, endoscopic ultrasound, and somatostatin receptor scintigraphy (SSRS) or gallium-68 DOTATATE PET/CT are recommended for detection of neuroendocrine tumors 3, 4
  • The American College of Radiology recommends neck ultrasound and/or sestamibi scan for parathyroid adenomas, pituitary MRI, abdominal CT/MRI for pancreatic and duodenal neuroendocrine tumors, and somatostatin receptor scintigraphy for MEN1 diagnosis 5, 6

Surveillance and Management

  • Annual biochemical screening for all three main manifestations starting from age 5-10 is recommended for patients with MEN1 syndrome, with the penetrance of MEN1 increasing with age (45% by age 30, 82% by age 50, 96% by age 70) 1
  • The following table summarizes the characteristics of MEN syndromes:
Syndrome Gene Prevalence Penetrance
MEN1 MEN1 1:20,000-40,000 45% by age 30, 82% by age 50, 96% by age 70
MEN2 RET 1:35,000 nearly 100% for MTC
MEN4 CDKN1B extremely rare not specified
HPT-JT CDC73 very rare 70-90%

1

  • The management of MEN syndromes requires a multidisciplinary approach, including surgery, medical therapy, and genetic counseling, with the goal of early detection, prevention of complications, and improvement of quality of life, as stated by the Endocrine Society 1
  • Surgical treatment for MEN1 includes parathyroidectomy, pancreatic surgery, and pituitary surgery, as recommended by the American College of Surgeons 1
  • Medical treatment for MEN1 includes cinacalcet for hyperparathyroidism, as well as somatostatin analogs and targeted therapies for pancreatic neuroendocrine tumors, according to the National Institute of Health 1
  • Genetic testing of first-degree relatives of patients with genetically confirmed MEN is recommended, as stated by the National Comprehensive Cancer Network 2
  • Surveillance for mutation-positive children should begin 5 years before the youngest age of onset in the family, with annual biochemical measurements, regular clinical examinations, and age-appropriate imaging studies, as recommended by the European Society of Endocrinology 7